Oncology Industry
Insights & Trends

April 21, 2020

Cancer Care in the Time of Covid-19

Cancer Care in the Time of Covid-19 While it seems much of our world has come to a halt since the spread of #covid19 , cancer […]
April 21, 2020

Kognitic Launches Covid-19 Insight Series

With over 1 million globally confirmed Covid-19 cases, the promise of bringing lives back to ‘normal’ seems ambiguous. Amidst several strategies to fight against the disease, […]
April 21, 2020

University of Penn Has Done It Again!

University of #Penn refuses to stop innovating. After having introduced CAR-T to the fight against #cancer, another Penn team has developed an a related technology which […]
April 21, 2020

Don’t Get Blindsided by Emerging Targets

Imalumab is the only drug targeting oxMIF to reach #clinicaltrials, but ultimately was terminated due to poor overall benefit-risk assessment. Now, OncoOne has announced that they […]
April 21, 2020

Tepotinib vs Capmatinib: A Race for Approval

Merck KGaA’s MET inhibitor, Tepotinib, received approval in Japan for #NSCLC yesterday, gaining a lead in the tight race against Capmatinib – Novartis’ MET inhibitor. The […]
April 21, 2020

Celebrating International Day of Women

On International Day of Women in Science. #Kognitic would like to celebrate the great strides which women are making in science. At our company women account […]
April 21, 2020

Take Time for World Cancer Day

Today is World Cancer Day, a day to reflect upon what strides we have been making toward helping the millions of patients battling cancer and focus […]
April 21, 2020

Lynparza Gets NICE’s Stamp of Approval

The National Institute for Health and Care Excellence has recommended #Lynparza for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritonealcancer in adults with […]
April 21, 2020

Kognitic: Stay One Step Ahead

#BeiGene presented its upcoming milestones for their #pipeline today at #JPM20, including projected approvals and submissions for #tislelizumab, #zanubrutinib, and #pamiparib. Why wait until the conference […]